Skip to content
SHORLA ONCOLOGY
  • About Us
  • Our Team
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • SH-105
    • SH-110
    • SH-111
    • SH-114
  • Careers
  • News
    • Company Updates
    • Media
  • Contact

Company Updates

Shorla Oncology Announces U.S. FDA Approval of Nelarabine Injection for the Treatment of T-Cell Leukemia

March 9th 2023

Read More

We were delighted to have been a presenting company at the BIOTECH Showcase 2023 in San Francisco recently!

January 16th 2023

Read More

Join Shorla Oncology at the BIO CEO and Investor Conference 2023

January 17th 2023January 16th 2023

Read More

Join Shorla Oncology at the Biotech Showcase 2023

January 5th 2023

Read More

Our CEO part of the “Cancer Across Borders – Ireland’s Reach” Panel Discussion

December 12th 2022

Read More

Join Shorla Oncology at CPhI Frankfurt 2022

October 19th 2022October 19th 2022

Read More

Shorla Oncology at Bio Europe 2022

October 13th 2022October 13th 2022

Read More

Our CTO spoke on the founders panel at Scale Ireland’s Annual Event

October 5th 2022September 12th 2022

Read More

Our CEO spoke at the LSX World Congress USA in Boston

July 21st 2022June 21st 2022

Read More

Older posts
Page1 Page2 … Page7

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

 

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP
PRIVACY POLICY
Company number: 618033
©SHORLA ONCOLOGY® 2022

© 2023 SHORLA ONCOLOGY • Built with GeneratePress
  • About Us
  • Our Team
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • SH-105
    • SH-110
    • SH-111
    • SH-114
  • Careers
  • News
    • Company Updates
    • Media
  • Contact